SOD2 and cancer: Combined with the prognostic analysis, we found that ESCC patients with high expression of c4_SOD2 had a poor prognosis, so we named them promoted cancer-associated pericytes (pro-CAPs), however, because c4_SOD2 may have dual anti-inflammatory and anti-tumor effects, we thought it would be more accurate to tentatively name it as double effect cancer-associated pericytes is more accurate.